Hogan Lovells advises CatalYm on €50m Series-C financing round

The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The biotechnology company CatalYm based in Martinsried, is developing innovative immunotherapies in cancer research. The funding will support the further clinical development of the lead product Visugromab, a monoclonal antibody designed to neutralise a specific protein (GDF-15) that tumours use to protect themselves from the body's own immune system. 

Hogan Lovells provided comprehensive legal advice to CatalYm in this financing round. The Life Sciences practice around partner Arne Thiermann has been supporting CatalYm on an ongoing basis.

Hogan Lovells Team for CatalYm GmbH

Dr. Nikolas Zirngibl (Partner), Thiemo Woertge (Senior Associate), Dr. Kilian Pfahl (Associate), (all Corporate/ Venture Capital, Munich); 

Arne Thiermann (Partner, Hamburg), Dr. Karolin Hiller (Senior Associate, Berlin) (both Strategic Operations Agreement Regulations/ Life Sciences).